Frederick Schnell named to new post of COA medical director

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Frederick Schnell was named medical director of the Community Oncology Alliance.

In this newly created position, Schnell will focus on issues related to oncology payment reform.

Schnell was a practicing community oncologist for 34 years, most recently as CEO, at Central Georgia Cancer Care in Macon, GA. He is a clinical assistant professor, Department of Medicine, Mercer University School of Medicine, Macon, GA. and a clinical assistant professor of hematology and oncology at the Winship Cancer Institute, Emory University School of Medicine.

Schnell has been the recipient of the Distinguished Cancer Clinician Award from the Georgia Cancer Coalition. He was a founding physician of COA, and has served as the third COA president, and as a member of the COA Board of Directors for many years.

“This is a crucial time for community oncology,” Schnell said in a statement. “There are obstacles and issues, to be sure, but the future is so much more positive and COA has more resources than at any time in its history.”

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login